Skip to main content

OFEV, VARGATEF (Boehringer Ingelheim Pty Ltd)

Product name
OFEV, VARGATEF
Date registered
Evaluation commenced
Decision date
Approval time
223 (255 working days)
Active ingredients
nintedanib esilate
Registration type
EOI
Indication

OFEV, VARGATEF (soft capsule) are now also indicated for the treatment of other chronic fibrosing Interstitial Lung Diseases (ILDs) with a progressive phenotype.

Help us improve the Therapeutic Goods Administration site